MapleStory Celebrates the Arrival of Hoyoung in New Update Today
4.12.2019 17:00:00 EET | Business Wire | Press release
Today, the iconic free-to-play global MMORPG, MapleStory, welcomes the new Anima thief class, Hoyoung. But that’s just the beginning. On December 18, the second part of the update titled Glory: Savior of Hope continues the story of Maple World after the defeat of the infamous Black Mage.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191204005385/en/
(Graphic: Business Wire)
Hoyoung, an all-new Anima thief class premiering in today’s update, brings a variety of skills and gameplay to Maple World using the Ritual Fan and Fan Tassel. With the help of Taotie, one of the four perils, Hoyoung looks to fix his mistake and reseal the monsters he accidentally unleashed upon the world.
The Glory: Savior of Hope update introduces the city of Cernium, which is amidst war. Fearing the worst as the enemy advances on the city walls, Prince Carlisle and the Maple Alliance invite players to join the fight to save Cernium from imminent danger and bring peace to Maple World!
In addition to the introduction of the new Hoyoung class, fans can participate in the Hoyoung Level-Up Event, allowing Maplers to level up for a chance to obtain an Arcane Umbra weapon. Maplers can also explore the newly revamped Global MapleStory exclusive storyline, discovering new quests and rewards along the way. In addition, players can meet the more powerful Jett with the 2nd update.
Additional Glory events will begin on December 18, including:
- New Glory Guard Missions - Missions will all provide chances to earn Glory, used to purchase exciting items in the Alliance Supply Depot.
- Glory Guard Rank Event - Joining the Glory Guard to save Maple World from impending danger offers players opportunities to level up through the ranks from Sentinel, Guardian, Master, Commander, and finally, Justicar.
- Alliance Supply Depot - Players can spend their hard earned Glory Coins in this one-stop shop for members of the Glory Guard.
- Camila's Bakery Christmas Event - Through December 31, players can celebrate the holidays with a variety of Christmas-themed events such as mini-games and puzzles. Rewards include holiday themed costumes, damage skins, and other fun goodies!
To learn more about the MapleStory Glory: Savior of Hope update, please visit http://maplestory.nexon.net/micro-site/glory .
Assets:
Social Media: Twitch / Facebook / Twitter / YouTube / Website
About MapleStory http://maplestory.nexon.net.
First released in North America in May 2005, MapleStory became one of the largest and most active free-to-play, side-scrolling MMORPGs in the world. With over 13 million registered players from its Global services alone (there are total seven MapleStory services around the world), the game continues to grow and evolve alongside its passionate community since launching over 15 years ago. There have been over 274 million characters created to date, which would make MapleStory the 4th highest populated country in the world.
About Nexon America Inc. http://www.nexon.net
Nexon America, a subsidiary of NEXON Co., Ltd. (“Nexon”) (3659.TO) with more than 80 live games operated across more than 190 countries, is a global leader in online games. Nexon America introduced micro-transactions and the free-to-play business model in the Western market, and is widely credited with unmatched global expertise in sophisticated live game operations, nurturing player communities, and for sustaining titles for years, even decades. Nexon is listed on the Tokyo Stock Exchange, and the company was placed on the Nikkei Stock Index 300 in 2017.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191204005385/en/
Contact information
Nathalie Nourian, B/HI for Nexon
nathalie_nourian@bhimpact.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura ® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 15:50:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). These data were presented (Abstract ID: P0851) today at the 2026 European Academy of Dermatology and Venereology (EADV) Symposium, being held May 7–9, 2026, in Athens, Greece. As previously reported, the TRuE-AD4 study met both of its co-primary endpoints at Week 8, with a statistically significantly higher proportion of patients on Opzelura versus vehicle cream achieving EASI75 (≥75% improvement in Eczema Area and Severity Index score from baseline) and, separately, IGA-TS (Investigator's Global Assessment Treatment Success, defined as an IGA score of 0 [clear] or 1 [almost clear] with at least a two-point improvement from baseline).1 Patients who
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 15:03:00 EEST | Press release
Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L. Saver, MD, UCLA, and Principal Investigator of DISTALS. “What’s important is that both the device and the trial were designed specifically for distal stroke. By using a device built for these small vessels and mea
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 15:00:00 EEST | Press release
Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have faced two critical dining pain points: [Pain Point 1] The Information Gap: Most available resources are tailored for tourists, making it difficult to find the true loc
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 15:00:00 EEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 14:00:00 EEST | Press release
In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football trading cards from 2031 onward. All products will be designed and developed through Fanatics Collectibles and produced under the Topps brand. As a part of the deal, Fanatics will bring the magic to young people in every region of the world and support youth football globally by distributing more than $150 million in collect
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom